Real-World Data Shows Similar Rate of Hypoglycemia Events With Insulin Glargine Injection, Insulin Degludec
Adults with type 2 diabetes who switched from basal insulin therapy to insulin glargine injection (Toujeo; Sanofi) experienced similar numbers of hypoglycemia events and decreases in average HbA1c as those who switched to insulin degludec, according to a pair of real-world studies presented recently at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Los Angeles, CA).
The 2 studies were retrospective observation analyses based on US databases of electronic medical records and claims. Researchers used propensity score matching to make treatment groups comparable and minimize bias.
The LIGHTNING study evaluated electronic medical records for 130,155 adults with type 2 diabetes treated with long-acting insulin in the US Optum-Humedica database. It compared 8456 patients switched from insulin glargine 100 units/mL to insulin glargine injection or to insulin degludec. Researchers found that the risk of severe hypoglycemia related to an inpatient or emergency department visit was comparable between patients receiving insulin glargine injection and insulin degludec. No differences in HbA1c were found.
Another study, DELIVER D, looked at electronic medical records for 22,492 adults with type 2 diabetes treated with long-acting insulin in the US Predictive Health Intelligence Environment database. The study focused on 1620 patients with type 2 diabetes who switched from insulin glargine 100 units/mL to insulin glargine injection or to insulin degludec.
During 6 months of follow up, the number of patients who experienced any hypoglycemia event was similar between those receiving insulin glargine injection and those receiving insulin degludec. Hypoglycemia events associated with hospital or emergency department visits were also comparable between the groups.
Reduction in average HbA1c levels was similar as well. Nearly 13% of patients receiving insulin glargine injection and 15.9% of patients receiving insulin degludec attained HbA1c below 7%. Some 44.2% of patients receiving insulin glargine injection and 44.6% of patients receiving insulin degludec achieved HbA1c below 8%.—Jolynn Tumolo